Clinical Trials Browser

Recruiting × Neoplasm, Residual × HMPL-013 × Clear all

NCT07136077 2026-06-01

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual